In this systematic review and network meta-analysis (NMA), we compared the clinical efficacy and safety of the agents according to their licensed indication in patients with NSCLC (free of anaplastic lymphoma kinase [ALK] positive and Epidermal growth factor receptor [EGFR] positive expression) for whom first-line treatments failed. The gene discussed is ALK; the disease is non-small cell lung carcinoma.